Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer

doi:10.12092/j.issn.1009-2501.2018.09.010

Abstract

Abstract:

AIM: To investigate the inhibitory effect of cisplatin combined with zoledronic acid on lung cancer cell PLA-801D proliferation. METHODS: Cell growth inhibitory rate of cisplatin combined with zoledronic acid was determined with MTT assay. The cell cycle was detected by flow cytometry. RESULTS: Cell proliferation was inhibited under the treatment of cisplatin, zoledronic acid alone. The inhibitory rate showed a dose dependent effect within a certain drug concentration range. Compared with single-drug treatment, the combined treatment of cisplatin and zoledronic acid showed a synergistic effect on cell growth inhibition. The highest inhibitory rate was found in sequential cisplatin+zoledronic acid group (cells were first incubated with cisplatin followed by zoledronic acid treatment 24 h later). In addition, compared with the control group, the S phase was longer after combined treatment of cisplatin and zoledronic acid. CONCLUSION: Sequential treatment of cisplatin and zoledronic acid show the strongest inhibitory effect on the cell proliferation of lung cancer. The ranged inhibitory effect may be related with the change of cell cycle.

Key words: cisplatin, zoledronic acid, lung cancer, cell growth inhibitory rate, cell cycle

CLC Number:

R965.2

QIN Boyu, WANG Gang, QI Xiaoguang, WANG Yajie, SUN Qiong, SUN Shengjie. Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1027-1030.

References

［1］孙燕,管忠震,廖美琳，等.肺癌骨转移诊疗专家共识(2014版)［J］.中国肺癌杂志,2014,95(2):57-72.
［2］Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study［J］. Lung Cancer, 2007, 57(2): 229-232.
［3］Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities［J］.Nat Rev Cancer, 2002, 2(8): 584-593.
［4］Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs［J］. J Clin Oncol, 2003, 21(7): 1404-1411.
［5］Williams G, Pazdur R, Temple R.Assessing tumor-related signs and symptoms to support cancer drug approval［J］. J Biopharm Stat, 2004, 14(1): 5-21.
［6］Isla D,Afonso R,Bosch-Barrera J,et al.Zoledronic acid in lung cancer with bone metastases:a review［J］.Expert Rev Anticancer Ther,2013,13(4):421-426.
［7］Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction［J］. Br J Cancer, 2010, 102(6): 1010-1017.
［8］茆勇, 马凤锦, 黄朝晖，等.顺铂联合唑来膦酸对肺癌A549细胞增殖的影响及其机制［J］.中华实验外科杂志, 2011, 28(11): 1939-1940.
［9］Ibrahim T, Liverani C, Mercatali L, et al.Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines［J］. Int J Oncol, 2013, 42(4): 1263-1270.
［10］You Y, Li H, Chen J, et al.Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway［J］. Oncol Lett, 2017, 13(3): 1840-1846.
［11］Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial［J］. Cancer, 2004, 100(12): 2613-2621.
［12］Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair［J］. J Biol Chem, 1994, 269(2): 787-790.
［13］王增, 卢红阳, 翁琳.唑来瞵酸抗肿瘤作用的临床研究进展［J］.中国临床药理学与治疗学, 2011, 16(8): 945-950.
［14］陈芳君，王增，蔡鑫君，等. 靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究［J］. 中国临床药理学与治疗学, 2017, 22(1): 33-36.
［15］Guenther A, Gordon S, Tiemann M, et al.The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation［J］. Int J Cancer, 2010, 126(1): 239-246.
［16］Almubarak H, Jones A, Chaisuparat R, et al. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers［J］. J Carcinog, 2011, 10(1): 2.
［17］ Iguchi T, Miyakawa Y, Saito K, et al.Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells［J］. Int J Oncol, 2007, 31(2): 285-291.
［18］Ohnuki H, Izumi K, Terada M, et al.Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes［J］. Arch Oral Biol, 2012, 57(7): 906-917.
［19］Ozturk OH, Bozcuk H, Burgucu D, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study［J］.Cell Biol Int, 2007, 31(9): 1069-1071.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[6]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[7]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[8]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[9]	WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
[10]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[11]	ZHAO Ziwen, FAN Fangtian, JIANG Zhijun. Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 353-360.
[12]	YE Kaili, ZHENG Wen, YE Qifa, YANG Lan . Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
[13]	CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
[14]	LIU Yunfan, DU Yuemei, LIU Xiaoyi, GAO Liping. Effects of lycium barbarum polysaccharides on cis-dichlorodiamineplatinum (II)-induced apoptosis in mouse testis sertoli cells TM4#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 624-630.
[15]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.